Announcements Trials
Browse Landscape

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 57Observational 2Expanded_access 2

Sponsor

Cancer Type

Breast 2

Conditions

HER2-positive Breast Cancer 1Breast Neoplasms 1

Interventions

Surveys and Questionnaires 543Blood Specimen Collection 446Surgical Procedures, Operative 164Observation 152Drug Therapy 142Radiotherapy 141Interviews as Topic 139Gene Expression Profiling 129Biopsy 117Magnetic Resonance Spectroscopy 116Immunohistochemistry 112Data Collection 95Polymerase Chain Reaction 87Specimen Handling 81Amplified Fragment Length Polymorphism Analysis 81Bevacizumab 78Microarray Analysis 76Flow Cytometry 69Neoadjuvant Therapy 68Watchful Waiting 66Magnetic Resonance Imaging 65Immune Checkpoint Inhibitors 61Nivolumab 60Immunotherapy 57Therapeutics 55Reverse Transcriptase Polymerase Chain Reaction 52pembrolizumab 50Ultrasonography 47Positron Emission Tomography Computed Tomography 47Hematologic Tests 46

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × tucatinib × Clear all
NCT06961331 2026-01-09

Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.

Pfizer

Completed
86 enrolled
Breast

Breast Neoplasms

NCT05253911 2025-12-04

TRACE

iOMEDICO AG

Completed
49 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡